ArticleDiabetes, obesity & metabolism2026
Proteomic Profiling of Plasma to Uncover Novel Intervention Targets and Prognostic Biomarkers for Chronic Liver Diseases.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Proteomic Profiling of Plasma to Uncover Novel Intervention Targets and Prognostic Biomarkers for Chronic Liver Diseases.Diabetes, obesity & metabolism · 2026Article
- Proteins at the intersection of circadian rhythms and metabolic dysfunction-associated steatotic liver disease: an 18-protein panel as a novel predictive biomarker set.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimsThe burden of chronic liver disease (CLD) is increasing. This study aims to identify protein markers for CLD and its progression, and develop a protein-based risk prediction model. MATERIALS AND
methodsWe used proteome-wide Mendelian randomization (MR), Bayesian colocalization and summary-data-based MR with proteomic data from deCODE Genetics to identify CLD-related proteins. Multivariable MR was used to assess independent protein effects. Protein-protein interaction, druggability and mediation analyses were conducted to prioritise therapeutic targets. We further constructed a protein risk score to predict CLD and composite hepatic event outcomes, comparing its performance with existing clinical predictors.
resultsGenetically predicted levels of 16, 5 and 4 plasma proteins were associated with metabolic dysfunction-associated steatotic liver disease (MASLD), alcoholic liver disease (ALD) and cirrhosis, respectively. IGSF3, FTCD, DCXR, ADH1B and ACY1 were associated with CLD progression. Genetically predicted five modifiable factors (body mass index, waist-hip ratio, glycated haemoglobin, type 2 diabetes, leisure television watching) were associated with CLD-related proteins. Proteomic-based models showed high predictive performance for ALD (C-index = 0.89), liver cancer (C-index = 0.84) and liver failure (C-index = 0.84) in a healthy population without liver diseases at baseline.
conclusionsThis study identified key circulating protein markers for CLD. Protein-based profiling demonstrated strong predictive potential for CLD and related outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.